New Medications for the Heart-Kidney-Metabolism Connection: SGLT2 Inhibitors and GLP-1 Drugs
SGLT2 inhibitors and GLP-1 receptor agonists show promise across the interconnected spectrum of obesity, diabetes, kidney disease, and heart failure.
Quick Facts
What This Study Found
SGLT2 inhibitors and GLP-1 receptor agonists provide multi-organ protection across the cardiovascular-kidney-metabolic syndrome spectrum.
Key Numbers
No specific effect sizes reported; this is a qualitative synthesis of recent CKM literature.
How They Did This
Narrative review synthesizing recent clinical evidence on cardiorenal protective medications in CKM syndrome.
Why This Research Matters
Treating these conditions in isolation misses their interconnection — drugs that address multiple organs simultaneously could transform care.
The Bigger Picture
The CKM framework is reshaping how clinicians think about metabolic disease — from treating individual conditions to managing an interconnected syndrome.
What This Study Doesn't Tell Us
Narrative review — does not systematically grade evidence quality. Long-term outcomes for combined therapy approaches are still emerging.
Questions This Raises
- ?Should SGLT2 inhibitors and GLP-1 drugs be combined routinely in CKM patients?
- ?Which CKM stage benefits most from early pharmacological intervention?
Trust & Context
- Key Stat:
- Multi-organ Both SGLT2 inhibitors and GLP-1 RAs provide benefits across heart, kidney, and metabolic systems simultaneously
- Evidence Grade:
- Review of clinical trial data — individual studies are strong but the review format does not systematically assess bias.
- Study Age:
- Published in 2025 in JCEM, capturing the latest CKM syndrome management approaches.
- Original Title:
- Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.
- Published In:
- The Journal of clinical endocrinology and metabolism, 110(8), 2105-2122 (2025)
- Authors:
- Pohlman, Neal, Patel, Prem N, Essien, Utibe R(2), Tang, Jasmyn J, Joseph, Joshua J
- Database ID:
- RPEP-13070
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
What is CKM syndrome?
A framework describing how obesity, diabetes, kidney disease, and heart disease are interconnected and worsen each other through shared metabolic and inflammatory pathways.
Can one medication treat heart, kidney, and metabolic problems together?
SGLT2 inhibitors and GLP-1 drugs both show benefits across multiple organ systems, making them ideal for CKM syndrome management.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13070APA
Pohlman, Neal; Patel, Prem N; Essien, Utibe R; Tang, Jasmyn J; Joseph, Joshua J. (2025). Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.. The Journal of clinical endocrinology and metabolism, 110(8), 2105-2122. https://doi.org/10.1210/clinem/dgaf295
MLA
Pohlman, Neal, et al. "Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.." The Journal of clinical endocrinology and metabolism, 2025. https://doi.org/10.1210/clinem/dgaf295
RethinkPeptides
RethinkPeptides Research Database. "Novel Cardiometabolic Medications in the Cardiovascular-Kidn..." RPEP-13070. Retrieved from https://rethinkpeptides.com/research/pohlman-2025-novel-cardiometabolic-medications-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.